Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
OPRM1, M-OR-1, LMOR, MOR, Mu-type opioid receptor, HMOP, Opioid mu receptor, MOP, MOR-1, MOR1, Mu opioid receptor, Opioid receptor, mu 1, KIAA0403, MOR-1C, Mu opiate receptor, Mu opioid receptor hMOR-1a, Opioid mu-type receptor, OPRM
Human, Monkey, Mouse, Rat, Horse, Pig
(tested or 100% immunogen sequence identity)
Bovine, Dog, Rabbit (at least 90% immunogen sequence identity)
IHC - Frozen
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents
ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
Synthetic peptide corresponding to aa384-398 (NHQLENLEAETAPLP) from the C-terminus of the cloned rat mu opioid receptor-1 (bovine thyroglobulin coupled by glutaraldehyde). Percent identity by BLAST analysis: Human, Chimpanzee, Gorilla, Monkey, Marmoset, Mouse, Rat, Horse, Pig, Opossum (100%); Bovine, Dog, Rabbit, Platypus (93%); Turkey, Chicken (80%).
Mu opioid receptor, C-terminal domain. Specificity confirmed by immunodot-blot assay. No reactivity to the N-terminus, second extracellular loop or a different segment of the carboxy tail of the mu opioid receptor. No reactivity to either the delta or kappa opioid receptor. Species cross-reactivity: Human, rat and mouse.
Suitable for use in Immunofluorescence, Immunohistochemistry, and Western Blot. Immunohistochemistry: 1:500-1:1000 (Cy3 technique); 1:6000-1:10000 (Biotin/avidin-HRP technique). Dilute antibody in PBS, 0.3% Triton X-100. Incubate 18-24 hrs at 2-8?C. Perfusion Fixation: With 500 ml 0.1 M phosphate buffer, pH 7.4, 4% paraformaldehyde for 20-30 minutes. Post Fixation: 0.1 M phosphate buffer, pH 7.4, 4% paraformaldehyde for 1.5 hours at 4?C. Sections: 10um cryostat. Note that a change in the fixation or buffering system as used in our protocol may change the configuration of the protein, and therefore, may alter the reactivity with the tissue tested. Pre-adsorption with immunogen peptide at 10 ug/ml completely eliminates labeling.
0.09% Sodium Azide
Short term: 4°C. Long term: Store at -20°C. Avoid freeze-thaw cycles.
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone.